换一批
换一批Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
作者：
主题词
成年人(Adult);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);阿糖胞苷(Cytarabine);剂量效应关系, 药物(Dose-Response Relationship, Drug);女(雌)性(Female);人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);男(雄)性(Male);代谢清除率(Metabolic Clearance Rate);中年人(Middle Aged);寡脱氧核糖核苷酸类(Oligodeoxyribonucleotides);寡核苷酸类, 反义(Oligonucleotides, Antisense);核苷酸还原酶类(Ribonucleotide Reductases);治疗结果(Treatment Outcome)
DOI
10.1158/1078-0432.CCR-08-0109
PMID
18559610
发布时间
2024-03-20
- 浏览23
Clinical cancer research
3889-95页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
